However, the product candidate 1207 did achieve the primary endpoint of safety and tolerability. In addition to safety data, the study measured sensory perceptions of touch and warmth following a single topical administration of 1207 compared with placebo. Anesiva said it would not pursue the clinical development of this drug.
“While we are disappointed that we did not see positive efficacy in this trial, our primary focus is on our two most advanced pain product candidates – Zingo, for which we recently filed a new drug application, and 4975, which is expected to enter pivotal trials later this year,” stated John McLaughlin, CEO of Anesiva.